PT  - JOURNAL ARTICLE
ED  - ,
TI  - ▼Olodaterol—another LABA for COPD
AID  - 10.1136/dtb.2015.4.0319
DP  - 2015 Apr 01
TA  - Drug and Therapeutics Bulletin
PG  - 42--45
VI  - 53
IP  - 4
4099  - http://dtb.bmj.com/content/53/4/42.short
4100  - http://dtb.bmj.com/content/53/4/42.full
SO  - Drug Ther Bull2015 Apr 01; 53
AB  - ▼Olodaterol solution for inhalation (Striverdi Respimat—Boehringer Ingelheim) is a long-acting beta2 agonist (LABA) licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). This is the third LABA to be licensed in the UK for once-daily use for patients with COPD. DTB has previously reviewed the use of indacaterol and vilanterol in combination with fluticasone furoate (▼Relvar Ellipta).1,2 In this article we consider the evidence for olodaterol and whether it offers any advantages in the management of COPD.